CHIẾN LƯỢC CÁ THỂ HÓA TRONG QUẢN LÝ U LYMPHO THỂ NANG: VAI TRÒ CỦA CÁC YẾU TỐ TIÊN LƯỢNG
Follicular lymphoma (FL) is an indolent malignancy; while approximately 80% of patients exhibit favorable therapeutic responses, 20% will experience relapse within two years. Various prognostic indices have been established to identify and predict this high-risk cohort. Classical clinical systems: The FLIPI and FLIPI-2 scoring systems facilitate the prediction of overall survival (OS) and progression-free survival (PFS), whereas the GELF criteria are pivotal in determining the optimal timing to initiate chemoimmunotherapy. Dynamic response assessment: The POD24 event (progression of disease within 24 months) and the depth of metabolic response on PET/CT serve as independent prognostic metrics. They reflect the biological aggressiveness of the tumor and guide the transition toward novel cellular and immunotherapies. Genetic and molecular profiles: Monitoring minimal residual disease (MRD) kinetics via the t(14;18) translocation predicts the depth of remission. Integrated clinico-genomic models, such as the m7-FLIPI and POD24-PI, enable precise risk stratification. Notably, TP53 mutations indicate chemoresistance and confer an exceptionally dismal prognosis; EZH2 mutations predict favorable responses to chemoimmunotherapy and present opportunities for targeted therapies; while KMT2D mutations drive mechanisms that facilitate immune evasion by tumor cells.
Authors
- Minh Phương Vũ
- Hải Yến Dương
- Thi Van Oanh Kieu
- Hải Bằng Dương
- Tuấn Tùng Nguyễn
Institutions
- Hanoi Medical University (VN)
- Bạch Mai Hospital (VN)
Publication Details
- Journal
- Journal of Clinical Medicine Bach Mai Hospital
- Published
- 2026-11-21
- DOI
- https://doi.org/10.52322/jocmbmh.156.0303
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00